Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Heart Test Laboratories, Inc. ( (HSCS) ) has issued an announcement.
On December 15, 2025, HeartSciences Inc. announced that its Board of Directors approved an Indemnification Agreement for directors and executive officers. This agreement ensures that the company will indemnify and advance expenses to these individuals to the fullest extent allowed by Texas law, while also maintaining their coverage under the company’s insurance policies.
The most recent analyst rating on (HSCS) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on Heart Test Laboratories, Inc. stock, see the HSCS Stock Forecast page.
Spark’s Take on HSCS Stock
According to Spark, TipRanks’ AI Analyst, HSCS is a Underperform.
Heart Test Laboratories, Inc. faces significant financial challenges, with substantial losses and high leverage. The technical analysis indicates a bearish trend, and the valuation metrics are unattractive due to negative profitability. While recent corporate events are positive, they do not outweigh the fundamental financial weaknesses.
To see Spark’s full report on HSCS stock, click here.
More about Heart Test Laboratories, Inc.
Average Trading Volume: 50,134
Technical Sentiment Signal: Sell
Current Market Cap: $6.75M
For an in-depth examination of HSCS stock, go to TipRanks’ Overview page.